FRAME: A Phase I Trial of the Combination of Defactinib (VS-6063) (FAK Inhibitor) and VS-6766 (RO5126766) (CH5126776) (a Dual RAF/MEK Inhibitor) in Patients With Advanced Solid Tumours

Trial ID # NCT03875820; FRAME
Phase I
Drug Class Signaling Pathway Inhibitors: Integrins-FAK/FAK
Drug Name Defactinib
Alternate Drug Names VS-6063, PF-04554878
Drugs in Trial Defactinib, Avutometinib
Eligible Participant

Recurrent low grade serous ovarian cancer

Patients Enrolled

25, median 4 prior therapies (1-9)

Therapy Setting


Study Design

Open-Label, Non-randomized


ORR, PFS, evaluated per RECIST


RP2D [3.2 mg VS-6766 (2x/week)+200 mg defactinib (BID) q3/4 weeks]

ORR: 46% (n=24)
PFS: 23 months
11 KRAS MUT: ORR: 64%
9 KRAS WT: ORR: 44%


VS-6766 (CH5127677)+defactinib shows promising clinical activity in patients with low grade serous ovarian cancer including those who have been previously treated with a MEK inhibitor


Coma S et al. Synergistic antitumor efficacy of the dual RAF/MEK inhibitor VS-6766 with FAK inhibition for treatment of RAS-dependent solid tumor. Cancer Res (2021) Volume 81, Issue 13 Supplement, abstract 1425

Coma S et al. Poster

Banerjee S et al. Phase I study of the combination of the dual RAF/MEK inhibitor VS-6766 and the FAK inhibitor defactinib: Results of efficacy in low grade serous ovarian cancer. Annals of Oncology (2021) 32 (suppl_5): abstract 725MO

Contact Us
Contact Us

We are here to help! Send us a message below or give us a call at (858) 657-0282.